Surveillance of invasive fungal infections in hospitalized patients in Bangladesh
Surveillance for Invasive Fungal Infections in Selected Hospitals in Dhaka City, Bangladesh
This study is trying to find out how common serious fungal infections are in hospitalized patients in Bangladesh to help doctors diagnose and treat them better.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 800 (estimated) |
| Ages | 0 Months and up |
| Sex | All |
| Sponsor | International Centre for Diarrhoeal Disease Research, Bangladesh Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Dhaka) |
| Trial ID | NCT06103331 on ClinicalTrials.gov |
What this trial studies
This observational study aims to conduct surveillance for invasive fungal pathogens among hospitalized patients in Bangladesh, specifically at two tertiary care hospitals. It will collect various clinical samples, including respiratory samples, blood, urine, and biopsy tissues, from patients in intensive care units and general wards. The samples will be analyzed using microscopy, culture, and biochemical tests to identify pathogens such as Aspergillus, Candida, and Cryptococcus. The study seeks to enhance understanding of the burden of fungal infections and improve early diagnosis and treatment.
Who should consider this trial
Good fit: Ideal candidates include hospitalized patients of any age with immunosuppressive conditions or risk factors for healthcare-associated fungal infections.
Not a fit: Patients who are not hospitalized or do not have any risk factors for invasive fungal infections may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnosis and treatment of invasive fungal infections, potentially reducing morbidity and mortality among at-risk hospitalized patients.
How similar studies have performed: While the approach of fungal surveillance is established, the specific context and methodology in Bangladesh may provide novel insights into local fungal infection patterns.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Inclusion criteria: Must include all of the following criteria: 1. Admitted/hospitalized patients of any age and gender in tertiary-level acute care hospitals AND 2. Having any of the following co-morbid immunosuppressive conditions or risk factors for healthcare-associated fungal infections such as: * Chronic lung conditions including asthma, COPD * Hemodialysis patients, * diabetes, * Patients receiving chemotherapy or immunosuppressive drugs (e.g. corticosteroids, immunosuppressive drugs among organ transplant recipients), for ≥7 days * Patients with AIDS * Patients at risk of healthcare-associated infections (e.g., Patients under postoperative care, having a urinary catheter, with tracheal intubation, under ventilatory support, secured with intravenous (IV) cannula, any other invasive procedures, etc.) * Hospitalized Patients under prolonged injectable antibiotic treatment (\>7 days) * Prolonged hospitalization more than 7 days. * History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization AND 3. Patients or caregivers providing consent For children aged \<5 years, the age criteria and additional inclusion criteria will be as follows: * 0 to 59-month-old children of either sex admitted in hospital with any illness. * Have features of sepsis/pneumonia (based on clinical features below) And any of the following criteria: * Those who will fail to respond to injectable antibiotics or both 1st and 2nd line antibiotics (1st line- inj. Ampicillin plus gentamicin, 2nd line- inj. Ceftriaxone plus levofloxacin/gentamicin as per icddr,b hospital protocol) * Any child with SAM or h/o recent measles or any condition that may induce immune suppression plus fail to respond to injectable antibiotics/ 1st line antibiotics (1st line antibiotics- inj. Ampicillin +inj. Gentamicin) * Those who will develop late-onset hospital-associated infection (LOHAI) * Any child who will require ICU care for more than 7 days * Develop extensive thrush after taking long-term injectable antibiotics * History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization Exclusion Criteria: * History of taking antifungal drugs within 2 weeks * Not willing to give consent
Where this trial is running
Dhaka
- International Centre for Diarrheal Disease Research, Bangladesh (icddr,b) — Dhaka, Bangladesh (Recruiting)
Study contacts
- Principal investigator: Sayeeda Huq, MBBS,MIPH — International Centre for Diarrheal Diseases Research, Bangladesh
- Study coordinator: Sayeeda Huq, MBBS, MIPH
- Email: sayeeda@icddrb.org
- Phone: +8801678127723
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.